Compile Data Set for Download or QSAR
Report error Found 135 Enz. Inhib. hit(s) with all data for entry = 10603
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553970(US11325916, Example 1)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553971(US11325916, Example 2)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553972(US11325916, Example 3)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553973(US11325916, Example 4)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553974(US11325916, Example 5 | US11325916, Example 6)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553974(US11325916, Example 5 | US11325916, Example 6)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553976(US11325916, Example 7)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553977(US11325916, Example 8)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553978(US11325916, Example 9)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553980(US11325916, Example 11)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553981(US11325916, Example 12)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553982(US11325916, Example 13)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553983(US11325916, Example 14)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553984(US11325916, Example 15)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553985(US11325916, Example 16)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553986(US11325916, Example 17)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553987(US11325916, Example 18)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553988(US11325916, Example 19)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553990(US11325916, Example 20)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553992(US11325916, Example 21)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553993(US11325916, Example 22)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553994(US11325916, Example 23)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553995(US11325916, Example 24)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553996(US11325916, Example 25)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553997(US11325916, Example 26)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553998(US11325916, Example 27)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM553999(US11325916, Example 28)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554000(US11325916, Example 29)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554001(US11325916, Example 30)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554002(US11325916, Example 31)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554003(US11325916, Example 32)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554005(US11325916, Example 33)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554006(US11325916, Example 34)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554007(US11325916, Example 35)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554008(US11325916, Example 36)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554009(US11325916, Example 37)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554011(US11325916, Example 38)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554012(US11325916, Example 39)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554013(US11325916, Example 40)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554014(US11325916, Example 41)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554015(US11325916, Example 42)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554016(US11325916, Example 43)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554017(US11325916, Example 44)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554018(US11325916, Example 45)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554019(US11325916, Example 46)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554020(US11325916, Example 47)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554021(US11325916, Example 48)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554022(US11325916, Example 49)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554024(US11325916, Example 51)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM554025(US11325916, Example 52)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/15/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 135 total ) | Next | Last >>
Jump to: